主动脉瓣狭窄患者外科主动脉瓣置换术后接受他汀治疗与更好的长期结局相关
该研究基于瑞典全国5个注册数据库2006-2020年因主动脉瓣狭窄行单纯外科主动脉瓣置换术后存活6个月的患者,纳入11894例,评估他汀使用与主要不良心血管事件(MACE)的关联。多变量Cox回归调整后,持续他汀治疗与MACE风险降低相关(aHR 0.77,95%CI 0.71-0.83,P<0.001),主要由全因死亡降低驱动(aHR 0.70,95%CI 0.64-0.76,P<0.001),各亚组结果一致。作者认为他汀治疗可能对这类患者有益,需随机对照试验确立因果关系。
要点
- 术后持续他汀治疗与MACE风险降低相关(aHR 0.77,95%CI 0.71-0.83,P<0.001)。
- 全因死亡降低是主要驱动因素(aHR 0.70,95%CI 0.64-0.76,P<0.001)。
- 基线他汀发放率49.8%(5918/11894),10年后为51.0%(874/1713)。
核心结论
- 结果提示他汀治疗可能对因主动脉瓣狭窄行外科主动脉瓣置换术的患者有益。
- 需随机对照试验确立他汀治疗与结局改善之间的因果关系。
研究设计与样本
- 基于瑞典全国5个注册数据库的全国性人群队列研究,纳入2006-2020年因主动脉瓣狭窄行单纯外科主动脉瓣置换术后存活6个月的患者。
- 共纳入11894例患者,采用多变量Cox回归模型评估时间更新的他汀发放与长期结局的关联。
主要发现
- 基线时49.8%(5918/11894)的患者接受他汀发放,10年后为51.0%(874/1713)。
- 基线时3.6%的患者接受低剂量他汀,69.4%接受中等剂量,27.0%接受高剂量。
- 调整后,持续他汀治疗与MACE风险降低相关(aHR 0.77,95%CI 0.71-0.83,P<0.001)。
- 全因死亡降低是主要驱动因素(aHR 0.70,95%CI 0.64-0.76,P<0.001)。
- 各亚组结果一致。
关键数值与推荐
- 主要结局MACE定义为全因死亡、心肌梗死或卒中。
- 多变量Cox回归模型调整年龄、性别、合并症、瓣膜类型、手术年份和二级预防药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to evaluate the association between statin use after surgical aortic valve replacement for aortic stenosis and long-term risk for major adverse cardiovascular events (MACEs) in a large population-based, nationwide cohort. METHODS: All patients who underwent isolated surgical aortic valve replacement due to aortic stenosis in Sweden 2006-2020 and survived 6 months after discharge were included. Individual patient data from 5 nationwide registries were merged. Primary outcome is MACE (defined as all-cause mortality, myocardial infarction or stroke). Multivariable Cox regression model adjusted for age, sex, comorbidities, valve type, operation year and secondary prevention medications is used to evaluate the association between time-updated dispense of statins and long-term outcome in the entire study population and in subgroups based on age, sex and comorbidities. RESULTS: A total of 11 894 patients were included. Statins were dispensed to 49.8% (5918/11894) of patients at baseline, and 51.0% (874/1713) after 10 years. At baseline, 3.6% of patients were dispensed low dose, 69.4% medium dose and 27.0% high-dose statins. After adjustments, ongoing statin treatment was associated with a reduced risk for MACE [adjusted hazard ratio 0.77 (95% confidence interval 0.71-0.83). P < 0.001], mainly driven by a reduction in all-cause mortality [adjusted hazard ratio, 0.70 (0.64-0.76)], P < 0.001. The results were consistent in all subgroups. CONCLUSIONS: The results suggest that statin therapy might be beneficial for patients undergoing surgical aortic valve replacement for aortic stenosis. Randomized controlled trials are warranted to establish causality between statin treatment and improved outcome.
引用
- Pan E, Nielsen SJ, Landenhed-Smith M, et al. Statin treatment after surgical aortic valve replacement for aortic stenosis is associated with better long-term outcome. Eur J Cardiothorac Surg. 2024. PMID: 38273669. doi:10.1093/ejcts/ezae007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。